{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:20:22Z","timestamp":1783524022431,"version":"3.55.0"},"reference-count":122,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2017.00110","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T03:54:41Z","timestamp":1500522881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeted Treatment Options in Mastocytosis"],"prefix":"10.3389","volume":"4","author":[{"given":"M\u00e9lanie","family":"Vaes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur Samantha","family":"Benghiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11882-013-0392-6","article-title":"Primary mast cell disorders in children","volume":"13","author":"Fried","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1586\/ehm.12.12","article-title":"Diagnosis, progression patterns and prognostication in mastocytosis","volume":"5","author":"Sperr","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.5858\/arpa.2011-0325-RS","article-title":"Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review","volume":"136","author":"Stoecker","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"B\u00fcttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1006\/bcmd.1998.0191","article-title":"In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation","volume":"24","author":"Beghini","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/1096-8652(200012)65:4<307::AID-AJH10>3.0.CO;2-F","article-title":"Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His","volume":"65","author":"Pullarkat","year":"2000","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.13567","article-title":"Paediatric mastocytosis: a systematic review of 1747 cases","volume":"172","author":"M\u00e9ni","year":"2015","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archderm.1986.01660130084031","article-title":"Familial urticaria pigmentosa","volume":"122","author":"Fowler","year":"1986","journal-title":"Arch Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.exphem.2011.05.009","article-title":"Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis","volume":"39","author":"Wasag","year":"2011","journal-title":"Exp Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1136\/jmg.2003.015156","article-title":"A germline mutation in KIT in familial diffuse cutaneous mastocytosis","volume":"41","author":"Tang","year":"2004","journal-title":"J Med Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13578-016-0120-8","article-title":"Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis","volume":"6","author":"Ke","year":"2016","journal-title":"Cell Biosci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0889-8588(05)70295-1","article-title":"Mastocytosis and the skin","volume":"14","author":"Soter","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/archdermatol.2011.190","article-title":"Dermoscopic features of skin lesions in patients with mastocytosis","volume":"147","author":"Vano-Galvan","year":"2011","journal-title":"Arch Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.hoc.2011.09.012","article-title":"Systemic mastocytosis","volume":"25","author":"George","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"B38","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.iac.2014.02.001","article-title":"Neuropsychological features of adult mastocytosis","volume":"34","author":"Moura","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2222.2009.03210.x","article-title":"Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase","volume":"39","author":"Potier","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.clml.2015.07.644","article-title":"Systemic mastocytosis: clinical update and future directions","volume":"15","author":"Tremblay","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/ejh.12544","article-title":"Current treatment options in patients with mastocytosis: status in 2015 and future perspectives","volume":"94","author":"Arock","year":"2015","journal-title":"Eur J Haematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","article-title":"Imatinib targets other than BCR\/ABL and their clinical relevance in myeloid disorders","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/17474086.2016.1254036","article-title":"Clonal eosinophil and mast cell diseases: different in the same way?","volume":"9","author":"De Wilde","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/blood-2013-10-530642","article-title":"The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid\/lymphoid neoplasms with eosinophilia","volume":"123","author":"Schmitt-Graeff","year":"2014","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11899-015-0280-3","article-title":"Tyrosine kinase inhibitors and therapeutic antibodies in advanced eosinophilic disorders and systemic mastocytosis","volume":"10","author":"Gotlib","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.1002\/ajh.23942","article-title":"Bosutinib, a Lyn\/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis","volume":"90","author":"Randall","year":"2015","journal-title":"Am J Hematol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-13-0397","article-title":"Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing \u03b2-catenin signaling","volume":"13","author":"Jin","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"B70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"key":"B71","first-page":"17","article-title":"PKC412 \u2013 a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"B73","first-page":"3217","article-title":"First selective KIT D816V inhibitor for patients with systemic mastocytosis","author":"Evans","year":"2014"},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.477.477","article-title":"Preliminary safety and clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM)","author":"Drummond","year":"2016"},{"key":"B75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.beha.2010.07.003","article-title":"Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells","volume":"23","author":"Valent","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"44","author":"Borate","year":"2016","journal-title":"Leuk Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1096\/fj.14-250894","article-title":"CD52 is a molecular target in advanced systemic mastocytosis","volume":"28","author":"Hoermann","year":"2014","journal-title":"FASEB J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.exphem.2006.09.008","article-title":"Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils","volume":"35","author":"Krauth","year":"2007","journal-title":"Exp Hematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/leu.2015.16","article-title":"Aberrant expression of CD123 (interleukin-3 receptor-\u03b1) on neoplastic mast cells","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2015.348","article-title":"CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2016.00009","article-title":"Tolerogenic IDO(+) dendritic cells are induced by PD-1-expressing mast cells","volume":"7","author":"Rodrigues","year":"2016","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am J Pathol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1182\/blood-2011-06-359984","article-title":"mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells","volume":"118","author":"Smrz","year":"2011","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.4049\/jimmunol.180.7.4586","article-title":"Activation and function of the mTORC1 pathway in mast cells","volume":"180","author":"Kim","year":"2008","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/10428190903486220","article-title":"Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis","volume":"51","author":"Parikh","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e29925","DOI":"10.1371\/journal.pone.0029925","article-title":"The PI3-kinase\/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils","volume":"7","author":"Blatt","year":"2012","journal-title":"PLoS One"},{"key":"B92","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs","volume":"114","author":"Aichberger","year":"2009","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1182\/blood-2006-07-032714","article-title":"Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412","volume":"109","author":"Aichberger","year":"2007","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/1535-7163.MCT-13-0830","article-title":"Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity","volume":"13","author":"Macleod","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1038\/leu.2015.138","article-title":"Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia","volume":"29","author":"Wedeh","year":"2015","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","first-page":"9647","DOI":"10.18632\/oncotarget.14181","article-title":"Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis","volume":"8","author":"Lyberg","year":"2017","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1182\/blood-2009-07-231985","article-title":"AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit","volume":"115","author":"Lin","year":"2010","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.clml.2015.02.017","article-title":"A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients","volume":"15","author":"Cooper","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B103","first-page":"6","article-title":"The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)\/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603\/RATIFY [alliance])","author":"Stone","year":"2015"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1067\/mjd.2003.98","article-title":"Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology","volume":"48","author":"Brockow","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11882-009-0010-9","article-title":"The problem of anaphylaxis and mastocytosis","volume":"9","author":"M\u00fcller","year":"2009","journal-title":"Curr Allergy Asthma Rep"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish Network on Mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"B113","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"B114","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000083954","article-title":"Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes","volume":"136","author":"Florian","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis \u2013 a single-centre experience","volume":"44","author":"G\u00fclen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B116","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt.11.44","article-title":"Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis","volume":"3","author":"Gonz\u00e1lez-de-Olano","year":"2011","journal-title":"Immunotherapy"},{"key":"B117","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","article-title":"Omalizumab monotherapy for bee sting and unprovoked \u2018anaphylaxis\u2019 in a patient with systemic mastocytosis and undetectable specific IgE","volume":"104","author":"Kontou-Fili","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"903541","DOI":"10.1155\/2015\/903541","article-title":"Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab","volume":"2015","author":"Lieberoth","year":"2015","journal-title":"Case Rep Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:21:37Z","timestamp":1602548497000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":122,"alternative-id":["10.3389\/fmed.2017.00110"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2017.00110","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]},"article-number":"110"}}